

Press Release

Changes of Representative Directors and Directors

Tokyo, April 27, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “the Company”) today announced that at a meeting of its Board of Directors held today, it decided changes of Representative Directors and Directors as stated below. These changes are subject to approval at the Ordinary General Meeting of Shareholders to be held on June 19, 2017 and decision at the Board of Directors meeting scheduled for the same day.

1. Changes of Representative Directors

(New Representative Director candidate)

Kenji Yasukawa

(New) Representative Director, Executive Vice President

(Current) Senior Corporate Executive, Senior Vice President, CSTO & CCO

CSTO: Chief Strategy Officer

CCO: Chief Commercial Officer

(Representative Director to be retired)

Yoshirou Miyokawa

(Current) Representative Director, Executive Vice President

- Effective date of changes: June 19, 2017
- Reason for changes: Those changes are decided in order to pursue Astellas' growth strategies more vigorously by new leader.

- **Curriculum Vitae of new Representative Director candidate**

Name: Kenji Yasukawa

Date of Birth: June 7, 1960

Place of Birth: Tokyo

-Education

March 1986 University of Tokyo, Master of Science, Agriculture

July 2001 Showa University Graduate School of Pharmaceutical Sciences, Japan, Ph.D. in Pharmaceutical Sciences

-Career History

April 1986 Joined the Company (former Yamanouchi Pharmaceutical Co., Ltd.)

April 2005 Vice President, Project Management, Urology, the Company

June 2010 Corporate Executive of the Company, Therapeutic Area Head, Urology, Astellas Pharma Europe B.V.

October 2010 Corporate Executive of the Company, Therapeutic Area Head, Urology, Astellas Pharma Global Development, Inc.

April 2011 Corporate Executive, Vice President, Product & Portfolio Strategy, the Company

April 2012 Corporate Executive, Senior Vice President and Chief Strategy Officer, the Company

June 2012 Senior Corporate Executive, Senior Vice President and Chief Strategy Officer, the Company

April 2017 Senior Corporate Executive, Senior Vice President, Chief Strategy Officer and Chief Commercial Officer, the Company

Ownership of shares: 11,315 shares (as of March 31, 2017)

2. New Candidates of Directors

Director	Kenji Yasukawa
Outside Director	Mamoru Sekiyama
Outside Director	Keiko Yamagami

3. Directors to be retired

Director	Yoshirou Miyokawa
Outside Director	Yutaka Kase
Outside Director	Hironobu Yasuda

(Reference)

Curriculum Vitae of new Director candidates

Name: Mamoru Sekiyama

Date of Birth: August 14, 1949

-Career History

April 1974 Joined Marubeni Corporation

April 1997 General Manager, Power Project Dept.-I, Marubeni Corporation

April 1998 General Manager, Power Project Dept.-III, Marubeni Corporation

April 1999 Deputy General Manager, Power Project Div.; General Manager,
Power Project Dept. I, Marubeni Corporation

April 2001 Senior Operating Officer, Utility Infrastructure Div.; General
Manager, Overseas Power Project Dept., Marubeni Corporation

April 2002 Corporate Vice President, Chief Operating Officer, Plant, Power &
Infrastructure Div., Marubeni Corporation

April 2005 Corporate Senior Vice President, Chief Operating Officer, Plant,
Power & Infrastructure Projects Div., Marubeni Corporation

June 2006 Corporate Senior Vice President, Member of the Board, Marubeni
Corporation

April 2007 Corporate Executive Vice President, Member of the Board,
Marubeni Corporation

April 2009 Senior Executive Vice President, Member of the Board, Marubeni
Corporation

April 2013 Vice Chairman, Marubeni Corporation

April 2015 Corporate Adviser, Marubeni Corporation (present post)

Chairman, Marubeni Power Systems Corporation

Name: Keiko Yamagami

Date of Birth: March 22, 1961

-Career History

April 1987 Public Prosecutor, Yokohama District Public Prosecutors Office

April 2002 Coordinator, the Legislative Division, Criminal Affairs Bureau,
Ministry of Justice

January 2005 Counselor, the Legislative Division, Criminal Affairs Bureau,
Ministry of Justice

August 2005 Public Prosecutor, Supreme Public Prosecutors Office

August 2007 Deputy Director of Public Peace Department, Tokyo District
Public Prosecutors Office

July 2008 Deputy Director of Trial Department, Tokyo District Public
Prosecutors Office

April 2009 Trial Director, Yokohama District Public Prosecutors Office

April 2010 Registered as an attorney-at-law (Dai-ichi Tokyo Bar
Association)
Lawyer honorary member, Tokyo Seiwa Law Office (present
post)

4. The Board of Directors and the Audit & Supervisory Board as from June 19, 2017 (planned full members)

Members of the Board of Directors

Yoshihiko Hatanaka (Representative Director, President and Chief Executive Officer)

Kenji Yasukawa (Representative Director, Executive Vice President)

Etsuko Okajima (Outside Director)

Yoshiharu Aizawa (Outside Director)

Mamoru Sekiyama (Outside Director)

Keiko Yamagami (Outside Director)

Members of the Audit & Supervisory Board

Tomokazu Fujisawa (Audit & Supervisory Board Member)

Hiroko Sakai (Audit & Supervisory Board Member)

Toshiko Oka (Outside Audit & Supervisory Board Member)

Hitoshi Kanamori (Outside Audit & Supervisory Board Member)

Noriyuki Uematsu (Outside Audit & Supervisory Board Member)

###

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers

in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

Contacts for inquiries or additional information:

Astellas Pharma Inc.

Corporate Communications

TEL: +81-3-3244-3201 FAX: +81-3-5201-7473